Menarini Group's Elacestrant Marketing Authorization Applicati...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
FLORENCE, Italy and NEW YORK, Aug. 19, 2022 / PRNewswire-AsiaNet/ -- - Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from second-line (2L) and third-line (3L) ER+/HER2- advanced or metastatic breast cancer in the European Union...
Authors: LATEST ASIANET NEWS RELEASES